Secretin and tumor DNA in pancreatic cancer before surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how secretin, a natural hormone, affects tumor DNA in the blood of people with pancreatic ductal adenocarcinoma. The goal is to find better ways to predict outcomes for patients who are eligible for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma.
- A team of doctors has decided that surgery is a possible treatment for you.
- You may or may not have received chemotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This study looks at how tiny particles in blood (“exosomes”) carry signals between cells in people having pancreatic surgery. The goal is to understand these signals in different pancreatic conditions and treatment situations, which may help future care.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial studies bacteria found inside pancreatic tumors to see if they can help diagnose or predict the course of the disease. You may be eligible if you have a suspected pancreatic cancer and need a special biopsy (EUS-FNB).
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.